Abstract
39 chronic schizophrenic out-patients were given either fluphenazine decanoate or enanthate for a 1-year double-blind trial. Doses of 25 mg were given for the first 6 months and 37.5 mg for the last 6 months. For both agents the intervals between treatments lengthened significantly over the course of the trial. Fluphenazine decanoate showed a non-significant trend for a longer duration of action coupled with a significantly lower incidence of extrapyramidal side effects.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Ambulatory Care*
-
Chronic Disease
-
Decanoic Acids
-
Delayed-Action Preparations
-
Double-Blind Method
-
Drug Evaluation
-
Female
-
Fluphenazine / administration & dosage
-
Fluphenazine / adverse effects
-
Fluphenazine / therapeutic use*
-
Heptanoates
-
Humans
-
Injections, Intramuscular
-
Male
-
Middle Aged
-
Schizophrenia / drug therapy*
Substances
-
Decanoic Acids
-
Delayed-Action Preparations
-
Heptanoates
-
Fluphenazine